ANTITUBERCULOTIC DRUGS

Ladislav Mirossay

P. J. Šafárik University
Faculty of Medicine
Department of Pharmacology
Košice


TUBERCULOSIS



Microbacterias de la tuberculosis




TBC incidence in the world 2013





Symptoms of TBC






Mycobacterial cell wall



Mycobacteria produce a thick mycolate-rich outer covering
 it functions as an exceptionally efficient barrier



Mycobacterial cell wall:

- 1. outer lipids
- 2. mycolic acid
- 3. polysaccharides
- (arabinogalactan)
- 4. peptidoglycan
- 5. plasma membrane
- 6. lipoarabinomannan (LAM)
- 7. phosphatidylinositol mannoside
- 8. cell wall skeleton


Principles of TBC treatment



- Always treat with more than one drug
- Six month regimens are effective for susceptible isolates
- Consider treating all patients with Directly Observed Therapy, Short-course (DOTS), which consists of an initial intensive phase & a later continuation phase
- Extrapulmonary disease is treated like pulmonary disease
- Children are treated like adults with dose adjustments for weight
- Pediatric exceptions: miliary, bone/joints, meningitis
- Add 2 new drugs to a failing regimen

TBC multi-resistance





www.thinglink.com


First line antituberculotic drugs



- isoniazid (INH)
- rifampicin
- ethambutol
- pyrazinamide
- streptomycin



MOA – 1st line



ATP Synthesis

INH



MOA

bacterial cell wall inhibition

- bactericidal (growth phase)
- bacteriostatic (steady phase)

Kinetics


- good resorption, tissue penetration, intracellular localization, necrotic lesion penetration as well as CNS
- genetically determined acetylation

SE

- relatively low toxicity
- pyridoxin defficiency
 neurotoxicity risk
 (pyridoxin substitution)
- hepatotoxicity

#


 no cross resistance with other antituberculotics



The first-line antibiotic drug rifampicin (RIF) interferes with RNA transcription in Mycobacterium tuberculosis. RIF binds to the β-subunit of the DNA-dependent RNA polymerase enzyme complex and inhibits transcription of messenger RNA (mRNA). The mRNA transcripts are essential requirements for protein synthesis (translation).


• Mycobacterial RNA-polymerase inhibition

Rifampicin



- **Good tissue** & poor CNS penetration (but sufficient not only for TBC of the CNS, but also for CNS staphylococcal & listerial infections)
- Microsomal enzyme induction
- Irregular side effects:
- cutaneous (flushing, pruritus, rash, hyperpigmentation)
- respiratory (breathlessness)
- > **abdominal** (nausea, vomiting, abdominal cramps, diarrhea)
- flu-like symptoms (chills, fever, headache, malaise)
- hepatotoxicity (severe liver damage possible)
- orange-red urine color (benign)
- Fast resistance development possible (arises from mutations that alter residues of the *rifampicin* binding site on RNA polymerase)

Ethambutol (EMB) inhibits arabinosyltransferase (EmbB) and blocks arabinogalactan synthesis




Ethambutol (EMB) interferes with cell wall biosynthesis in *Mycobacterium tuberculosis* EMB \Downarrow the action of arabinosyl transferase (EmbB - a membrane-associated enzyme involved in the synthesis of arabinogalactan). Arabinogalactan is an essential structural component of the mycobacterial cell wall.

Ethambutol



- Regarded as the least toxic of the 1. line anti-TBC drugs - irregular side effects:
- possible optic neuritis (considered to be reversible following prompt withdrawal red-green color blindness)
- peripheral neuropathy
- > arthralgia
- It is a rare cause of acute, symptomatic liver injury (the addition of *ethambutol* to *isoniazid, rifampicin* or *pyrazinamide* does not appear to ît the rate of transient ALT elevations)
- Good CNS distribution (in TBC meningitis)
- Fast resistance development possible
- Not used in children below 6 years of age (it is difficult to detect *ethambutol* induced visual impairment)



The first-line antibiotic drug pyrazinamide (PZN) interferes with cell wall biosynthesis in Mycobacterium tuberculosis. PZN is a prodrug and is converted to an active form (pyrazinoic acid) by a nicotinamidase-peroxidase enzyme known as pyrazinamidase (PncA). Pyrazinoic acid inhibits the action of fatty acid synthetase I (FAT-I). FAT-I is involved in the synthesis of short-chain mycolic acids. Mycolic acids are essential structural components of the mycobacterial cell wall and are attached to the arabinogalactan layer.



Pyrazinamide



Active only in acidic pH

 Affects mycobacteria in fagozomes of macrophages (acidic pH)


CNS penetration

DDC 61748-012-06 DDC 61

SE

- It plasma urates
- hepatotoxicity in high doses
- fast resistance development

Streptomycin Aminoglycoside




• Aminoglycoside

(historically first antituberculotic – obsolete because of less toxic alternatives – *capreomycin, amikacin*)


- Bacterial proteosynthesis ↓
- i.m. application

Side effects

- ototoxicity
- nephrotoxicity



Summary of SE of the 1st line antituberculotics






Second line antituberculotic drugs



- capreomycin
- cycloserine
- amikacin
- claritromycin
- levofloxacin



Capreomycin



• **Peptide ATB** (Streptomyces capreolus)

- Proteosynthesis inhibitor
- Important for drugresistant TBC



• i.m. application

Side effects

- nephrotoxicity
- loss of hearing
- ataxia
- hypokalemia
- hypomagnesemia

Cycloserine



- Broad spectrum ATB
- Competitive U of cell wall synthesis
- Good tissue distribution including CNS
- Majority of drug eliminated unchanged in urine


Side effects

• Mainly CNS neurological side effects (headache, iritability, depression, cramps, psychotic status)

In TBC resistant to other drugs



Amikacin Aminoglycoside



- Irreversibly binds to to 30S subunit of bacterial ribosome:
- blocks recognition step in proteosynthesis
- Primarily in extracellular fluid (highly hydrophylic):
- penetrates BBB when meninges inflammed
- i.v. infusion

- Prevalence to amikacin
 resistance is low (most MDR remain susceptible)
- It is active against atypical mycobacteria:
- also for Gram- infections resistant to gentamicin or tobramycin



Clarithromycin Macrolide



Sensitivity:

- Most *Mycobacterium avium* complex (MAC)
 bacteria consisting of:
- Mycobacterium avium
- > Mycobacterium intracellulare
- Isolated from both
 AIDS & non-AIDS
 patients

Uses:

- Disseminated mycobacterial infections due to:
- Mycobacterium avium or
- Mycobacterium intracellulare
- > also in AIDS patients



Levofloxacin Fluoroquinolone



Tuberculous meningitis (твм):

Uses:

- guidelines generally recommend treatment with *rifampicin, INH, pyrazinamide & streptomycin* or *ethambutol* (for 3 months in the intensive phase, followed by at least a 6-month period of treatment with *rifampicin & INH*)
- however, CSF penetration of *rifampicin* (the key drug in TBM treatment), ethambutol & streptomycin is poor; *INH* & *pyrazinamide* penetrate more readily
- Ievofloxacin excellent CSF penetration, with AUC_c/AUC_p = 75% (compared with gatifloxacin 35% & ciprofloxacin 14%)
- it has also demonstrable in vitro activity, tolerability, good bioavailability & ease of administration
- in combination with above mentioned anti-TBC agents





Hello! My name is Sergeant Bobby Bacteria. I am a member of an army that is avidly fighting the War on Drugs